Form 4: Monopar Therapeutics Director Sells Over $356K in Stock Following Option Exercise

Sentiment:

Insider Transaction Report 16 July 2025 9:06 PM

Monopar Therapeutics director Kim R. Tsuchimoto sold 8,904 shares of common stock for approximately $356,000 after exercising stock options at a nominal price.

Worse than expectedA director sold a significant number of shares (8,904) on the open market. While this was a result of exercising options, the act of selling can be perceived as a lack of confidence in future stock price appreciation by some investors.

Summary

Monopar Therapeutics director Kim R. Tsuchimoto exercised stock options to acquire 8,904 shares of common stock at an exercise price of $0.005 per share on July 14, 2025.
Immediately following the exercise, Ms. Tsuchimoto sold all 8,904 shares at a weighted average price of $40.0012 per share.
The total proceeds from the sale amounted to approximately $356,170.66.
After these transactions, Ms. Tsuchimoto beneficially owns 11,486 shares of Monopar Therapeutics common stock.
The options exercised included 4,200 shares granted on April 4, 2016, and 4,704 shares granted on February 20, 2017, both for services as a director and prior officer.

Sentiment

Score: 4

Explanation: The sale of shares by a director, even following an option exercise, can be interpreted as a slightly negative signal by the market, suggesting a potential lack of confidence in near-term stock price appreciation.

Positives

The director realized a significant gain from the exercise and sale of stock options, indicating the options were deeply in the money.
The transaction demonstrates the value creation for long-term equity holders and management incentives.

Negatives

The sale of shares by a director, even following an option exercise, can be interpreted by some investors as a lack of confidence in the company's near-term stock price appreciation.

Risks

Insider selling, particularly by a director, may be perceived as a negative signal by the market, potentially leading to downward pressure on the stock price.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: May interpret the director's sale as a negative signal, potentially influencing investment decisions.

Key Dates

Date	Description
04/04/2016	Grant date for 4,200 stock options to Ms. Tsuchimoto.
02/20/2017	Grant date for 4,704 stock options to Ms. Tsuchimoto.
07/14/2025	Date of stock option exercise and subsequent sale of shares.
07/16/2025	Date the Form 4 was signed and filed.

Keywords

Monopar Therapeutics, MNPR, SEC Form 4, insider trading, stock options, director sale, equity compensation, Kim R. Tsuchimoto

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.